The global antibody-mediated rejection prevention market is poised for remarkable expansion, reflecting the increasing demand for innovative solutions in organ transplant care. In 2023, the market is valued at USD 89 million, and it is projected to grow at a compelling compound annual growth rate (CAGR) of 16% through 2033. By the end of this period, the market valuation is expected to soar to USD 528.31 million.
The significant growth trajectory underscores the heightened focus on mitigating antibody-mediated rejection, a critical complication in organ transplantation that often compromises the success of the procedure. With advancements in immunology and biotechnology, novel therapeutics and preventive measures are being developed, driving the market forward.
Key Market Drivers:
- Rising Transplantation Rates: The increasing prevalence of chronic diseases leading to organ failure has escalated the number of organ transplants globally.
- Technological Innovations: Continued advancements in monoclonal antibodies and immune-modulating therapies are enhancing treatment efficacy.
- Growing Awareness: Greater awareness among healthcare providers and patients about AMR risks and solutions is boosting demand for preventive strategies.
Market Outlook:
The antibody-mediated rejection prevention market presents a lucrative opportunity for stakeholders, including pharmaceutical companies, research institutions, and healthcare providers. With a robust pipeline of innovative products and an expanding patient base, the market is anticipated to witness sustained growth over the forecast period.
Industry players are encouraged to leverage this momentum by accelerating research and development efforts, forging strategic collaborations, and ensuring equitable access to emerging therapies.
Key Takeaways from the Market Study:
- The immunomodulators market is expected to grow at a CAGR of 6.3% over the forecast period.
- From 2018 to 2022, sales increased significantly at a CAGR of 14%.
- The global monoclonal antibodies segment was worth USD 186 million in 2021
- The global monoclonal antibodies segment is expected to grow at a CAGR of 11% between 2023 and 2033.
- The global market for antibody-mediated rejection prevention is expected to be worth USD 528.31 million.
“The population of people with end-stage kidney disease is getting older. Nearly half of all new patient populations are over 65, with one-third being over 70. As a result, late kidney transplant failure is common among the elderly, which is expected to drive the antibody-mediated rejection prevention market,” says the FMI analyst.
Increased Market Demand: Get In-Depth Analysis and Insights with Our Complete Report!
Key Market Players:
Key players in the Antibody-mediated Rejection Prevention market are CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly, and Company, Bristol-Myers & Squibb Company.
Some of the latest developments are below:
- Horizon Therapeutics plc disclosed in February 2021 that it will purchase Viela Bio, Inc. to substantially expand its product portfolio and flourish its rare disease medical portfolio.
- The trial’s Independent Data Monitoring Committee has recommended that the evaluation of Jardiance® (empagliflozin) in grownups with chronic kidney disease (CKD) be halted early. Following an official interim analysis that fulfilled predefined criteria for favorable efficacy, the Medical Research Council (MRC) Population Health Research Unit reported in March 2022.
Key Segments Profiled in the Antibody-mediated Rejection Prevention Market Survey
By Treatment:
- Monoclonal Antibodies
- Cysteine Protease Inhibitors
- Immunomodulators
- Plasmapheresis
By End User:
- Hospitals
- Specialty Clinics
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube